December 7, 2020
A key health ministry panel on December 4 recommended approval for a batch of new medicines and indications including Takeda Pharmaceutical’s ALK inhibitor brigatinib. However, it held off a decision on Seikagaku’s osteoarthritis treatment as panel members asked for clarifications...read more